Lurbinectedin is a chemotherapy drug that is used to treat certain types of cancer. Immunotherapy, on the other hand, is a type of cancer treatment that helps the body's immune system fight cancer. There is no specific recommended dosage for lurbinectedin and immunotherapy as the dosage varies depending on the type of cancer, stage of the disease, and other factors.

According to Drug Patent Watch [1], the recommended dosage for lurbinectedin is 3.2 mg/m2 administered as an intravenous infusion over 60 minutes every 21 days. However, the dosage may be adjusted based on the patient's individual response to the treatment.

A study published in the Journal of Clinical Oncology [2] evaluated the combination of lurbinectedin and pembrolizumab, an immunotherapy drug, in patients with relapsed small-cell lung cancer. The study used a dosage of 3.2 mg/m2 of lurbinectedin administered every 21 days and 200 mg of pembrolizumab administered every three weeks. The study found that the combination therapy produced early efficacy signals in patients with relapsed small-cell lung cancer.

It is important to note that the dosage and treatment regimen for lurbinectedin and immunotherapy should be determined by a healthcare professional based on the patient's individual medical history, current health status, and other factors.

In conclusion, there is no specific recommended dosage for lurbinectedin and immunotherapy as the dosage varies depending on the type of cancer, stage of the disease, and other factors. The recommended dosage for lurbinectedin is 3.2 mg/m2 administered as an intravenous infusion over 60 minutes every 21 days. A study found that the combination of lurbinectedin and pembrolizumab produced early efficacy signals in patients with relapsed small-cell lung cancer using a dosage of 3.2 mg/m2 of lurbinectedin administered every 21 days and 200 mg of pembrolizumab administered every three weeks. However, the dosage and treatment regimen for lurbinectedin and immunotherapy should be determined by a healthcare professional based on the patient's individual medical history, current health status, and other factors.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.onclive.com/view/lurbinectedin-plus-pembrolizumab-produces-early-efficacy-signals-in-relapsed-small-cell-lung-cancer